The use of varenicline to treat nicotine dependence among patients with cancer

Psycho-Oncology

Volumn 26, Issue 10, 2017, Pages 1526-1534

  Price, Sarah ^a   Hitsman, Brian ^b   Veluz Wilkins, Anna ^b   Blazekovic, Sonja ^a   Brubaker, Tarah R ^a   Leone, Frank ^c   Hole, Anita ^a   Wileyto, E Paul ^a   Langer, Corey ^a   Kalhan, Ravi ^b   Patel, Jyoti ^b   Schnoll, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

affect; cancer; cognition; oncology; smoking cessation; varenicline

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; NICOTINE; NICOTINIC AGENT; VARENICLINE;

ADULT; COUNSELING; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PROCEDURES; PSYCHOLOGY; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADULT; BENZAZEPINES; BUPROPION; COUNSELING; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NICOTINE; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; VARENICLINE;

EID: 85030993029     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.4166     Document Type: Article

References (31)

1. US Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
2. Mowls DS, Brame LS, Martinez SA, et al. Lifestyle behaviors among US cancer survivors. J Cancer Surviv 2016 [Epub ahead of print].
3. Ostroff JS, Copeland A, Borderud SP, et al. Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers. Nicotine Tob Res 2016;18(5):1067–1075.
4. Farley A, Aveyard P, Kerr A, et al. Surgical lung cancer patients’ views about smoking and support to quit after diagnosis: a qualitative study. J Cancer Surviv 2016;10(2):312–319.
5. Balmford J, Leifert JA, Jaehne A. “Tobacco dependence treatment makes no sense because”…: rebuttal of commonly-heard arguments against providing tobacco dependence treatment in the hospital setting. BMC Public Health 2014;14:1182.
6. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute: Bethesda, MD, 2015.
7. Jorenby DE, Hays JT, Rigotti N, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.
8. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results form a randomized, open-label trial. Thorax 2008;63:717–724.
9. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009;65(2):144–149.
10. Rollema H, Hajós M, Seymour PA, et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009;78(7):813–824.
11. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121(2):221–229.
12. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013;159:390–400.
13. Park ER, Japuntich S, Temel J, et al. A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot clinical trial. J Thorac Oncol 2011;6(6):1059–1065.
14. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD, US Public Health Service, 2008.
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22–33.
16. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168(12):1266–1277.
17. Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015;175(4):504–511.
18. Lerman C, Schnoll RA, Hawk LW Jr, et al. for PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomized, double-blind placebo-controlled trial. Lancet Respir Med 2015;3(2):131–138.
19. Heatherton TF, Kozlowski L, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119–1127.
20. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063–1070.
21. Lai JS, Butt Z, Wagner L, et al. Evaluating the dimensionality of perceived cognitive function. J Pain Symptom Manage 2009;37(6):982–995.
22. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009;11(3):234–239.
23. Brown R, Burgess E, Sales S, et al. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 1998;12:101–112.
24. Lerman C, Kaufmann V, Rukstalis M, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 2004;140:426–433.
25. Schnoll RA, Patterson F, Wileyto P, et al. Efficacy of extended duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010b;152:144–151.
26. Balmford J, Borland R, Hammond D, et al. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res 2011;13(2):94–102.
27. Schnoll RA, Martinez E, Tatum KL, et al. A buproprion smoking cessation clinical trial for cancer patients. Cancer Causes Control 2010a;21(6):811–820.
28. Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluation the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23(4):793–801.
29. Foulds J, Russ C, Yu C, et al. Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. Nicotine Tob Res 2013;15(11):1849–1857.
30. NCCN. Clinical Practice Guidelines in Oncology: Smoking Cessation, Version I. 2015. J Natl Compr Canc Netw 2015;13(4):xliv.
31. Buchanan TS, Berg CJ, Cox LS, et al. Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report. Nicotine Tob Res 2012;14(9):1083–1091.